ASSOCIATION OF HIGH LIPOPROTEIN(a) LEVELS WITH CORONARY ARTERY PATENCY DURING THE FIRST YEAR AFTER PERCUTANEOUS CORONARY INTERVENTIONS

Objective: to study an association of high lipoprotein(a) [Lp(a)] levels with the development of restenosis and the progression of coronary
atherosclerosis after percutaneous coronary interventions (PCI) in patients with chronic coronary heart disease (CHD).

Subjects and methods. From 502 enrolled patients (mean age 54.7 ± 8.9 years), 92 underwent routine percutaneous transluminal coronary angioplasty (PTCA), 270 had PTCA with the bare metal stent (BMS) being implantation, 140 had PTCA using drug-eluting stents (DES). Functional
classes III and IV angina have been registered in 337 (67 %) patients; history of one myocardial infarction (MI) was noted in 234 (47 %) cases, 171 (34 %) had experienced 2 or more MIs. Blood samples for lipid and Lp(a) measurements were taken in all the patients. Restenosis was defined as at least 50 % lumen narrowing of the coronary artery segment after angioplasty. Coronary atherosclerosis progression was established in cases of the new occlusion occurring, as well as identifying a 10 % decrease in lumen diameter in comparison with baseline angiograms.

Results. Repeated coronary angiography revealed the signs of restenosis in 103 of 243 patients. Dividing patients into 3 groups according to the type of intervention demonstrated that the level of Lp(a) (median 25–75 % quartiles) was significantly higher in the restenosis group after implantation of BMS (33; 11–62 and 16; 6–39 mg/dl, respectively; p = 0.014) versus those who had undergone DES implantation (23; 10–30 and 20; 6–60 mg/dl; p = 0.7) or balloon angioplasty (17; 4–48 and 9; 4–36 mg/dl; p = 0.3). Patients with progression of coronary atherosclerosis had difference only in Lp(a) levels compared to the group without progression (36; 13–62 versus 12; 4–26 mg/dl, p < 0,001.

Conclusion. During the first year after elective PCI Lp(a) concentration determined the severity of coronary atherosclerosis in non-culprit lesions
and associated with the risk of in-stent restenosis after BMS, independly of conventional risk factors.

1. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population. The Copenhagen City Heart Study. Circulation 2008;117:176–84.

2. Clarke R., Peden J.F., Hopewell J.C., et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361(26):2518–28.

3. Erqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk of

4. vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol

5. ;55(19):2160–7.

6. MacLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA Sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132–7.

7. Curtis J.P, Schreiner G., Wang Y., et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients.JAm Coll Cardiol 2009;54:903–7.

8. Desmarais R.L., Sarembock I.J., Ayers C.R., et al. Elevated serum Lp(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403–9.

9. Kamitani T., Taniguchi T., Miyai N., et al. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation. Circ J 2005;69:644–9.

10. Alaigh P., Hoffman C.J., Korlipara G., et al. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 1998;18:1281–6.

11. Ribichini F., Steffenino G., Dellavalle A., et al. Plasma lipoprotein(a) is not a predictor for

12. restenosis after elective high-pressure coronary stenting. Circulation 1998;98:1172–7.

13. Wehinger A., Kastrati A., Elezi S., et al. Lipoprotein (a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999;33:1005–12.

14. Zairis M.N., Ambrose J.A., Manousakis S.J., et al. The impact of plasma levels of C-reactive

15. protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary

16. stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study.

17. J Am Coll Cardiol 2002;40:1375–82.

18. Gazzaruso C., Garzaniti A., Falcone C., et al. Restenosis after intracoronary stent placement:

19. can apolipoprotein(a) polymorphism play a role? Int J Cardiol 2003;87:91–8.

20. Matsumoto Y., Daida H., Watanabe Y., et al. High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease. J Atheroscler Thromb 1998;5:47–53.

21. Igarashi Y., Aizawa Y., Satoh T., et al. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein(a). Circ J 2003;67:605–11.

22. Uchida T., Inoue T., Kamishirado H., et al. Prediction of short-term progression or regression of atherosclerotic coronary artery disease by lipoprotein(a): a quantitative coronary angiographic study. Angiology 2003;54:641–6.

23. Morita Y., Himeno H., Yakuwa H., Usui T. Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006;70:156–62.

24. Terres W., Tatsis E., Pfalzer B., et al. Rapid angiographic progression of coronary heart disease in patients with elevated lipoprotein(a). Circulation 1995;91:948–50.

25. Hartmann M., von Birgelen C., Mintz G., et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol 2006;48:446–52.

26. Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюллетень экспериментальной биологии и медицины

27. ;4:398–401.

28. Austen G.W., Edwards J.E., Frye R.L., et al. A reporting system on patients evaluated for coronary heart disease. Circulation 1975;51:5–40.

29. Smith S.C. Jr., Dove J.T., Jacobs A.K., et al. АСС/АНА Guidelines for percutaneous сoronary intervention (revision of the 1993 PTCA Guidelines) – executive summary. A Report of the American College of Cardiology/American Heart Association Task Forse on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019–41.

30. Beatt К., Serruys P., Rensing В., Hugenoltz P. Restenosis after coronary angioplasty: New standard of clinical studies. J Am Coll Cardiol 1990;15:491–8.

31. Lloyd G.W., Jackson G., Foley D.P., et al. The influence of plasma lipoprotein(a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis 2001;158:445–54.

32. Grainger D.J., Kemp P.R., Liu A.C., et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460–2.

33. Lawn R.M., Pearle A.D., Kunz L.L., et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996;271:31367–71.

34. Etingin O.R, Hajjar D.P, Hajjar K.A., et al. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991;266:2459–65.

35. Daida H., Lee Y.J., Yokoi H., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994;73:1037–40.